Hermetica Superfood Encyclopedia
The Short Answer
Daedalea quercina produces lanostane-type triterpene derivatives—including 16-O-acetylpolyporenic acid C and 16alpha-acetoxy-24-methylene-3-oxolanost-8-en-21-oic acid—alongside phenolic compounds such as ellagic acid (0.45 ± 0.09 µg/g) and 6,7-dihydroxycoumarin (0.34 ± 0.03 µg/g) that collectively drive free-radical scavenging activity. Methanol extracts have demonstrated in vitro antioxidant and enzyme inhibitory properties in preliminary laboratory studies, though no human clinical trials have yet quantified effect sizes or established therapeutic doses.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordDaedalea quercina benefits
Oak Mazegill — botanical close-up
Health Benefits
**Antioxidant Activity**
Phenolic compounds, particularly ellagic acid and 6,7-dihydroxycoumarin, donate hydrogen atoms to neutralize reactive oxygen species, reducing oxidative stress markers in cell-based assays.
**Enzyme Inhibition Potential**
Crude extracts have shown inhibitory activity against oxidative and hydrolytic enzymes in vitro, suggesting a possible role in modulating biochemical pathways linked to metabolic disease, though human validation is absent.
**Phenolic-Mediated Cytoprotection**: Ellagic acid, the dominant phenolic at 0
45 µg/g, is widely documented in other systems to protect cells from lipid peroxidation and DNA oxidative damage via Nrf2 pathway activation.
**Triterpene Bioactivity**: Novel lanostane-type triterpenoids isolated from D
quercina exhibit structural features common to triterpenes with demonstrated anti-inflammatory and cytotoxic properties in related polypore species, warranting further mechanistic study.
**Free Radical Scavenging**
Gallic acid and trans-cinnamic acid, detected in trace concentrations, contribute additive radical-scavenging capacity through aromatic hydroxyl group electron donation in vitro.
**Potential Metabolic Enzyme Modulation**: Preliminary data suggest that D
quercina extracts may inhibit enzymes relevant to glucose and lipid metabolism, positioning it as a candidate for exploratory metabolic health research pending rigorous study design.
Origin & History
Natural habitat
Daedalea quercina is a wood-decay bracket fungus native to Europe, North America, and temperate Asia, characteristically growing on dead or dying oak (Quercus spp.) stumps and logs, though it occasionally colonizes other hardwoods such as chestnut and beech. It thrives in deciduous and mixed forests under conditions of moderate humidity and moderate temperatures, fruiting perennially as a tough, corky, fan-shaped polypore with a distinctive labyrinthine (maze-like) pore surface. Unlike many edible fungi, it is not cultivated commercially for food but has attracted phytochemical research interest for its secondary metabolites.
“Daedalea quercina has been recognized and named in European mycological literature since Linnaeus described it in the 18th century, with the species epithet quercina reflecting its characteristic association with oak trees. Unlike better-studied medicinal polypores such as Ganoderma lucidum or Trametes versicolor, D. quercina does not appear prominently in classical Chinese, Ayurvedic, or European herbal medicine traditions, and no substantial ethnopharmacological record of its deliberate use as a remedy has been documented in indexed sources. The fungus is primarily noted in forestry and ecology literature as a white-rot wood decay organism of economic importance to timber health. Its entry into biomedical research is recent and driven by systematic screening programs for bioactive compounds in underexplored fungal species rather than by revival of documented traditional use.”Traditional Medicine
Scientific Research
The current evidence base for Daedalea quercina consists exclusively of in vitro phytochemical and biochemical studies; no human clinical trials, animal intervention studies with controlled endpoints, or pharmacokinetic investigations have been published in indexed literature accessible as of 2024. Phytochemical profiling studies have identified and quantified phenolic compounds using HPLC methods, and antioxidant capacity has been evaluated using standard cell-free assays such as DPPH and ABTS radical scavenging, though reported values vary by extraction method and solvent. Triterpene isolation studies have characterized novel lanostane derivatives structurally, providing foundational chemistry data but no efficacy or safety endpoints. The overall evidence is preclinical and descriptive; effect sizes in human populations, bioavailability, and dose-response relationships are entirely unknown, placing D. quercina at an early exploratory research stage.
Preparation & Dosage
Traditional preparation
**Raw Fruiting Body**
Not consumed as food due to tough, corky, leathery texture; not suitable for culinary preparation.
**Methanol/Ethanol Extract (Research Grade)**
Used in laboratory studies at variable concentrations; no standardized commercial extract exists and no human dose has been established.
**Hot Water Decoction (Traditional/Exploratory)**
Analogous to preparations used for other woody polypores; no documented traditional dosing protocol specific to D. quercina has been recorded in peer-reviewed ethnobotanical literature.
**Standardization**
No commercial standardization to specific triterpene or phenolic content has been established; ellagic acid content of 0.45 ± 0.09 µg/g in methanol extracts is the only quantified benchmark in published literature.
**Effective Dose Range**
Entirely undetermined; no clinical or animal dose-finding studies exist.
**Timing/Administration Notes**
No evidence-based guidance on timing, cycling, or administration route is available for this ingredient.
Nutritional Profile
As a woody bracket fungus, Daedalea quercina is not consumed nutritionally, and comprehensive proximate analysis data are not available in published literature. The fruiting body contains structural polysaccharides (primarily glucans and chitin in the cell wall), which are common to all fungi but have not been characterized for this species specifically. Identified bioactive phytochemicals include ellagic acid (0.45 ± 0.09 µg/g), 6,7-dihydroxycoumarin (0.34 ± 0.03 µg/g), vanillin (0.07 ± 0.02 µg/g), gallic acid (0.02 ± 0.01 µg/g), and trans-cinnamic acid (0.02 ± 0.01 µg/g) in methanol extracts, alongside lanostane-type triterpenes including 16-O-acetylpolyporenic acid C. Concentrations of phenolics are relatively low compared to edible medicinal mushrooms, and bioavailability of these compounds from D. quercina has not been studied; the chitin-rich cell wall likely limits compound extraction and absorption without processing.
How It Works
Mechanism of Action
The antioxidant mechanism of Daedalea quercina is primarily attributed to its phenolic content: ellagic acid and 6,7-dihydroxycoumarin donate protons to quench free radicals directly, while their polyhydroxyl structures allow electron delocalization that stabilizes oxidized intermediates. Ellagic acid in particular is known in parallel systems to activate the Nrf2/ARE transcriptional pathway, upregulating endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, though this specific pathway has not been confirmed experimentally in D. quercina extracts. The lanostane-type triterpenes—structurally analogous to compounds in Ganoderma and Poria species—likely interact with inflammatory signaling mediators such as NF-κB and cytokine cascades, a hypothesis consistent with their chemical scaffold but unconfirmed for this species. Enzyme inhibitory activity observed in vitro may involve competitive or allosteric inhibition of oxidoreductases, though the precise binding targets and kinetics for D. quercina-specific compounds remain uncharacterized.
Clinical Evidence
No clinical trials involving human participants have been conducted or reported for Daedalea quercina as a supplement or therapeutic agent as of the current literature review. Available studies are limited to in vitro antioxidant assays and phytochemical isolation work, which cannot be extrapolated to establish clinical efficacy, safety margins, or recommended dosing in humans. The absence of animal pharmacology studies also means that even preclinical proof-of-concept data for any specific health outcome is lacking. Confidence in any therapeutic claim for D. quercina is therefore very low, and all putative benefits are hypothesis-generating rather than evidence-based.
Safety & Interactions
No formal safety studies, toxicology assessments, or adverse event data exist for Daedalea quercina in humans or animal models, meaning the safety profile is entirely unestablished and caution is warranted for any supplemental use. Drug interactions have not been studied; however, given that ellagic acid in high concentrations from other sources has shown inhibitory effects on cytochrome P450 enzymes (notably CYP1A2 and CYP3A4) in vitro, theoretical interactions with medications metabolized by these pathways cannot be excluded. No contraindications, maximum tolerable doses, or reproductive safety data are documented; use during pregnancy or lactation is not recommended due to the complete absence of safety evidence. Individuals with known fungal allergies or immunocompromised status should exercise particular caution, consistent with general guidance for all mushroom-derived preparations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Daedalea quercina (L.) Pers.Oak MazegillMaze-gill fungusAgaricus quercinus L.Trametes quercina
Frequently Asked Questions
What are the main bioactive compounds in Daedalea quercina?
Daedalea quercina contains phenolic compounds including ellagic acid (0.45 ± 0.09 µg/g), 6,7-dihydroxycoumarin (0.34 ± 0.03 µg/g), gallic acid, vanillin, and trans-cinnamic acid in methanol extracts. It also contains novel lanostane-type triterpene derivatives such as 16-O-acetylpolyporenic acid C and 16alpha-acetoxy-24-methylene-3-oxolanost-8-en-21-oic acid, which are structurally related to bioactive triterpenes found in other medicinal polypores.
Is there clinical evidence supporting Daedalea quercina for human health?
No human clinical trials have been published for Daedalea quercina; current evidence is limited entirely to in vitro phytochemical and antioxidant assays. While these laboratory studies confirm the presence of bioactive compounds with antioxidant and enzyme inhibitory activity, they cannot establish efficacy, safety, or appropriate doses in humans, and all health claims remain unsubstantiated at the clinical level.
What is the antioxidant mechanism of Daedalea quercina?
The antioxidant activity of D. quercina extracts is primarily attributed to phenolic compounds—especially ellagic acid and 6,7-dihydroxycoumarin—which donate hydrogen atoms or electrons to neutralize free radicals in cell-free assay systems. These compounds share structural features with phenolics known to activate the Nrf2/ARE antioxidant pathway in other systems, though this specific mechanism has not been confirmed for D. quercina extracts experimentally.
Is Daedalea quercina safe to consume as a supplement?
The safety of Daedalea quercina for human consumption has not been evaluated in any published toxicology or clinical study, making it impossible to confirm its safety at any dose. Its tough, corky fruiting body is not edible in the traditional culinary sense, and in the absence of safety data, supplemental use—particularly during pregnancy, lactation, or alongside prescription medications—is not advisable.
How does Daedalea quercina differ from better-known medicinal mushrooms like Ganoderma?
While D. quercina shares lanostane-type triterpene chemistry with Ganoderma lucidum (reishi), it has been studied far less extensively, with no clinical trials, no established commercial extracts, and no documented traditional medicinal use compared to Ganoderma's centuries of use in East Asian medicine and dozens of clinical investigations. D. quercina's phenolic profile—dominated by ellagic acid rather than Ganoderma's ganoderic acids—also distinguishes its phytochemical character, though both remain in the bracket fungus family Polyporaceae.
What forms of Daedalea quercina are available as supplements, and how do extraction methods affect potency?
Daedalea quercina is typically available as fruiting body extracts, mycelium extracts, or whole dried powder, with hot water extraction being the most common method for capturing polysaccharides and phenolic compounds. Alcohol-based extractions may concentrate different bioactive compounds like ellagic acid, while dual-extraction methods (hot water followed by alcohol) aim to capture a broader spectrum of active constituents. The extraction solvent and temperature significantly influence the concentration of bioactive compounds, making standardized extracts potentially more consistent in potency than raw powder forms.
Are there any known drug interactions with Daedalea quercina supplements?
Limited clinical data exists on Daedalea quercina drug interactions; however, its enzyme inhibitory properties suggest potential interactions with medications metabolized by cytochrome P450 enzymes, similar to other medicinal mushrooms. Individuals taking anticoagulants, antiplatelet agents, or immunosuppressants should consult a healthcare provider before supplementing, as mushroom polysaccharides may have mild anticoagulant and immunomodulatory effects. Currently, there are no well-documented severe interactions, but research on this specific species remains limited.
What populations might benefit most from Daedalea quercina supplementation based on current research?
Individuals seeking antioxidant support and those exposed to oxidative stress conditions may benefit from Daedalea quercina, particularly given its ellagic acid content and enzyme-inhibiting properties demonstrated in cell-based studies. However, robust clinical evidence is lacking, and most research has been conducted in vitro or in animal models rather than human trials. People with compromised immune function or those interested in functional mushroom nutrition represent potential user populations, though individual benefits remain largely uncharacterized.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w daedalea-quercina-daedalea-quercina-l-pers curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
